Collegium Pharmaceutical, Inc., a specialty pharmaceutical company focused on the development of innovative treatments for chronic pain is pleased to announce the appointment of Gino Santini to its Board of Directors. Mr. Santini most recently served as Senior Vice President of Corporate Strategy and Business Development at Eli Lilly and Company, where he led corporate strategy and long-range planning, M&A, new product licensing, innovative financing of internal development projects and the expansion of Lilly Ventures in the U.S. and China.

“We are very pleased to have Gino join our Board of Directors at this pivotal time in the Company’s history. As we progress our lead candidate, an extended-release, tamper-resistant oxycodone product for the treatment of chronic pain (COL-003), toward NDA filing, Gino ‘s expertise in commercialization and business development will be instrumental in assisting the Company in choosing our strategic path,” said Michael Heffernan, CEO of Collegium.

Mr. Santini recently retired after a 27-year career at Eli Lilly and Company, where he held positions of increasing responsibility, serving as Senior Vice President, Corporate Strategy and Policy; President, U.S. Operations; and President, Women’s Health Business Unit. Mr. Santini is a past Chairman of the Board of the National Pharmaceutical Council and of Noble of Indiana, a nonprofit agency serving individuals with developmental disabilities in Central Indiana. In addition to Collegium, Mr. Santini currently serves on the boards of AMAG Pharmaceuticals (NASDAQ: AMAG), Horizon Pharma (NASDAQ: HZNP), Sorin SpA (SRN.MI) and Allena Pharmaceuticals.

“The Company’s DETERx® Technology has the potential to address a large unmet clinical and societal need in the use of opioids for the treatment of chronic pain. I look forward to working with the Collegium team to advance the lead product to the market,” said Mr. Santini.

About DETERx® Technology

The DETERx® drug delivery platform consists of a multi-particulate matrix formulation in a capsule. While developed primarily to provide tamper-resistant properties to protect against common methods of tampering such as chewing, crushing, snorting and extraction for IV injection, the multi-particulate design is expected to enable patients with difficulty swallowing to open the capsule and administer the contents on food or via a gastronomy tube, while maintaining the extended release properties of the product. DETERx® technology can be used with drugs that are commonly abused such as opioids and amphetamines, as well as drugs that have narrow therapeutic windows that would benefit from protection against misuse such as breaking, crushing, grinding or dissolving the product. The formulation platform is covered by U.S. and international patents and patent applications. COL-003 is the first of a number of product candidates using the DETERx® platform.

About Collegium Pharmaceutical, Inc.

Collegium Pharmaceutical, Inc. is a specialty pharmaceutical company focused on developing a portfolio of products that incorporate its patent-protected DETERx® formulation platform for the treatment of chronic pain. The DETERx® oral drug delivery technology provides extended-release delivery, unique tamper-resistant properties, and flexible dose administration options. For more information, visit the Company’s website at www.collegiumpharma.com.